Why Mainz Biomed (MYNZ) Shares Are Gaining Today

Mainz Biomed N.V. (NASDAQ:MYNZ) inked a pact with Liquid Biosciences, a bio-analytics company leveraging its proprietary AI analysis technology platform (EMERGE), to enhance the detection and diagnosis of colorectal cancer (CRC).

Key attributes of EMERGE that make it superior to mainstream AI and machine learning analytical solutions include its computational speed, ability to handle millions of variables, and ability to operate agnostically without any assumptions or constraints.

The partnership expands on Mainz Biomed's initial deployment of EMERGE for examining the ColoFuture study's findings, which revealed promising results, including a 94% sensitivity for detecting colorectal cancer with a specificity of 97% and an 80% sensitivity for identifying advanced adenomas.

According to the agreement, the application of EMERGE within Mainz Biomed's development pipeline will now also encompass the examination of its eAArly DETECT study (the U.S. segment of the ColoFuture clinical trial), as well as the upcoming U.S. pivotal FDA PMA trial (ReconAAsense), which could, upon positive outcomes, allow Mainz Biomed to enhance the existing test's performance and bring to market a new benchmark for self-administered CRC screening tools.

The eAArly DETECT clinical trial, a multi-center feasibility study, is proceeding with the enrollment of 265 participants across 22 sites and is anticipated to share its findings in Q4 2023.

The end goal is to create a singular, stable machine learning/AI-based algorithm using the evolutionary EMERGE platform, to be incorporated into the reporting mechanism of the forthcoming product generation.

Since launching the EMERGE bio-analytics platform, Liquid Biosciences is widely considered to be the premier analytical partner to the life sciences industry. Its technology has been deployed in over 240 projects for Big Pharma and emerging therapeutic and diagnostic companies.

"As artificial intelligence continues to disrupt every aspect of the healthcare sector, we are excited to establish a robust partnership with a genuine leader in the field as we head into the final development stage of our next-generation CRC screening test," commented Guido Baechler, Chief Executive Officer of Mainz Biomed.

Price Action: MYNZ shares are trading higher by 9.09% to $3.00 on the last check Tuesday.

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.

Benzinga

Benzinga

AI Meets Oncology! Mainz Biomed Inks Pact With Liquid Biosciences To Develop Next-Gen Colorectal Cancer Screening Test